-transparent.png){kind=logo}
Disulfiram (Antabuse) is being used in outpatient clinical trials to determine its efficacy as a treatment for cocaine dependence. This inpatient randomized, double-blind, placebo-controlled, within-subjects study was conducted to determine whether disulfiram (placebo, 250 or 500 mg/day) alters responses to acute intranasal cocaine (placebo, 1 or 2 mg/kg) administration. Effects of disulfiram on cocaine pharmacokinetics, physiological, and behavioral responses were determined. Disulfiram treatment increased plasma cocaine concentrations three to six times and significantly increased cocaine-associated cardiovascular responses, but did not significantly alter behavioral responses to cocaine. These interactions should be considered in the decision regarding disulfiram treatment in cocaine dependent patients.
E F McCance-Katz, and
T R Kosten, and
P Jatlow
March 2007,
Drug and alcohol dependence,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
April 2006,
Current psychiatry reports,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
June 2008,
Pharmacology, biochemistry, and behavior,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
November 2000,
Experimental and clinical psychopharmacology,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
September 1993,
Neuroscience letters,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
January 2017,
Journal of psychopharmacology (Oxford, England),
E F McCance-Katz, and
T R Kosten, and
P Jatlow
January 1998,
Journal of studies on alcohol,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
November 1993,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
January 2017,
Human psychopharmacology,
E F McCance-Katz, and
T R Kosten, and
P Jatlow
March 2012,
Journal of the experimental analysis of behavior,
